• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Mirum Pharmaceuticals Inc. (Amendment)

    12/29/23 4:01:02 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRM alert in real time by email
    SC 13D/A 1 nea16-mirum_18785.htm NEW ENTERPRISE ASSOCIATES 16, L.P. / MIRUM PHARMACEUTICALS, INC. -- SCHEDULE 13D/A(#2E) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Mirum Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    604749101

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    December 21, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 604749101

    13D Page 2 of 9 Pages    

    Item 1.  Security and Issuer.

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D amends and supplements the Schedule 13D originally filed on July 30, 2019, and Amendment No. 1 filed on June 23, 2023, relating to the common shares, $0.0001 par value (the “Common Stock”), of Mirum Pharmaceuticals, Inc. (the “Issuer”), having its principal executive office at 950 Tower Lane, Suite 1050, Foster City, California 94404.

     

    Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1 thereto).

     

     

     

    Item 2.  Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 16, L.P. (“NEA 16”), NEA Partners 16, L.P. (“NEA Partners 16”), which is the sole general partner of NEA 16; and NEA 16 GP, LLC (“NEA 16 LLC” and, together with NEA Partners 16, the “Control Entities”), which is the sole general partner of NEA Partners 16; and

     

    (b) Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Scott D. Sandell (“Sandell”) and Paul Walker (“Walker”) (together, the “Managers”). The Managers are the managers of NEA 16 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 16, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Behbahani is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815. The address of the principal business office of Chang, Makhzoumi, and Walker is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001.

     

    The principal business of NEA 16 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 16 is to act as the sole general partner of NEA 16. The principal business of NEA 16 LLC is to act as the sole general partner of NEA Partners 16. The principal business of each of the Managers is to manage the Control Entities, NEA 16 and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 16 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 16 and NEA Partners 16 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

     

     

     

    CUSIP No. 604749101

    13D Page 3 of 9 Pages    

     

     

     

    Item 4.  Purpose of Transaction.

    Not applicable.

     

     

     

    Item 5.  Interest in Securities of the Issuer.

    Each of the Reporting Persons has ceased to own beneficially five precent (5%) or more of the Issuer’s Common Stock.

     

     

     

    Item 6.  Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

     

     

    Item 7.  Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

    CUSIP No. 604749101

    13D Page 4 of 9 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 29th day of December, 2023.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Chief Executive Officer 

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

      

    NEA 16 GP, LLC

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

     

     

     

     

     

    CUSIP No. 604749101

    13D Page 5 of 9 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Paul Walker 

     

     

     

     

    */s/ Stephanie Brecher           

    Stephanie Brecher

    As attorney-in-fact

     

     

    This Amendment No. 2 to Schedule 13D was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     

     

     

     
     

     

    CUSIP No. 604749101

    13D Page 6 of 9 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Mirum Pharmaceuticals, Inc.

     

    EXECUTED this 29th day of December, 2023.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:          *                                

     Scott D. Sandell

     Chief Executive Officer 

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

      

    NEA 16 GP, LLC

     

    By:          *                                

    Scott D. Sandell

    Chief Executive Officer

     

     

     

     

     

     

    CUSIP No. 604749101

    13D Page 7 of 9 Pages    

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Paul Walker 

     

     

     

     

     

    */s/ Stephanie Brecher           

    Stephanie Brecher

    As attorney-in-fact

    This Agreement relating to Schedule 13D was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

     

     

    CUSIP No. 604749101

    13D Page 8 of 9 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. 

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 604749101

    13D Page 9 of 9 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

     

     

     

     

     

     

    Get the next $MIRM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIRM

    DatePrice TargetRatingAnalyst
    5/19/2025$73.00Buy
    H.C. Wainwright
    4/17/2024$48.00Buy
    Stifel
    12/18/2023$60.00 → $58.00Buy
    H.C. Wainwright
    11/20/2023$37.00Overweight
    Analyst
    11/13/2023$60.00Overweight
    Morgan Stanley
    10/24/2023$50.00Overweight
    Cantor Fitzgerald
    10/17/2023$62.00Outperform
    Evercore ISI
    9/20/2023$70.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $MIRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednesday, May 21st at 9:00 AM ET. Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. About Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. is a biopharmaceutical compan

      5/14/25 4:05:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 9, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,230 shares of common stock and 26,585 restricted stock units ("RSUs") to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $44.27 per share, Mirum's closing trading price on May 9, 2025, and will vest over four years, with 25%

      5/9/25 6:00:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GLOBAL CONTROLLER Howe Jolanda sold $107,343 worth of shares (2,415 units at $44.45), decreasing direct ownership by 50% to 2,426 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/19/25 5:40:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GLOBAL CONTROLLER Howe Jolanda exercised 58,215 shares at a strike of $2.67 and sold $2,554,763 worth of shares (57,606 units at $44.35), increasing direct ownership by 14% to 4,841 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:09 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND COO Radovich Peter converted options into 14,440 shares and sold $348,364 worth of shares (7,879 units at $44.21), increasing direct ownership by 54% to 18,672 units (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 9:30:07 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Financials

    Live finance-specific insights

    See more
    • Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

      5/7/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d

      4/30/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      - 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee

      2/26/25 4:01:00 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $73.00

      5/19/25 8:53:13 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Mirum Pharmaceuticals with a new price target

      Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00

      4/17/24 7:27:53 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Mirum Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously

      12/18/23 11:54:26 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/18/25 5:04:31 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/12/25 4:51:20 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

      4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

      3/10/25 5:12:58 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/15/25 3:32:46 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.

      SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      5/14/25 11:59:51 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Mirum Pharmaceuticals Inc.

      10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)

      5/7/25 4:08:12 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

      For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

      2/21/25 11:48:20 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

      Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

      5/19/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

      - 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

      1/13/25 8:30:00 AM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MIRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 4:37:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:55:40 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

      SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

      11/14/24 12:25:52 PM ET
      $MIRM
      Biotechnology: Pharmaceutical Preparations
      Health Care